Skip to content. | Skip to navigation


Personal tools

Dr. David Scott, MD


DScott8@bccancer.bc.ca


Short Biography

 

Dr. David Scott, MBChB, PhD, FRACP, FRCPA

Clinician-Scientist

 

Clinical and Research Roles:

Assistant Professor, Department of Medicine, University of British Columbia

Clinician Scientist, BC Cancer

Deputy Head of Department – Department of Lymphoid Cancer Research, BC Cancer Research Centre

Translational Sciences Co-Chair of the Lymphoma Tumor Group of ECOG

 

Dr. Scott is an Assistant Professor in the Department of Medicine at the University of British Columbia and a Scientist in the Department of Lymphoid Cancer Research (BC Cancer). He gained his MBChB/PhD from the University of Auckland, New Zealand. Following his clinical fellowships in hematology, he took up a post-doctoral fellowship at BC Cancer with Drs. Gascoyne and Connors. In 2014, he was appointed as a Clinician-Scientist at BC Cancer, receiving the inaugural BC Cancer Foundation Clinical Investigator Award. Dr. Scott’s research focusses on unravelling the determinants of treatment failure in B-cell lymphoid cancers (lymphoma and CLL) and translating this knowledge into assays to guide treatment management. He has authored over 60 peer-reviewed papers, has been an invited speaker at many conferences and receives research funding from Genome Canada, the Terry Fox Research Institute, the Lymphoma Research Foundation and the National Institutes of Health. He is the Clinical Director of BC Cancer’s Centre for Lymphoid Cancer, a member of the Lymphoma/Leukemia Molecular Profiling Project (LLMPP) and the Translational Sciences Co-Chair of the Lymphoma Tumor Group of ECOG. 

 

Scott Laboratory

 

The focus of the research in the Scott laboratory is aimed at improving outcomes of patients with lymphoid cancers through precision medicine. This involves unravelling the molecular determinants of treatment failure, applying cutting edge technology to patient biopsies, and then translating that knowledge into assays that can be used to guide treatment management. These approaches have led to the development of prognostic and predictive biomarkers for classical Hodgkin lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma that are applicable to routinely produced formalin-fixed paraffin-embedded biopsies – allowing these assays to be used in clinical practice. 

  

The poor outcomes seen when patients experience treatment failure have led to an emphasis on the biology of these cancers at the time point of relapse, exploring high-risk genetic features and evolution of tumors as they are exposed to immuno-chemotherapy. The Scott laboratory is now leading and co-ordinating correlative studies in clinical trials of treatment of relapsed and refractory aggressive B-cell lymphoma. Finally, the Scott laboratory has broadened the biobank at BC Cancer to enable the expansion of this research into chronic lymphocytic leukemia (CLL).

 

Collaborations

 

The translational focus of the Scott laboratory is made possible through collaborations within the BC Cancer’s Centre for Lymphoid Cancer with physicians and pathologists in Vancouver and across BC, along with Scientists at the BC Cancer Research Centre and the Genome Sciences Centre. The Scott laboratory is also part of international collaborative efforts, notably the Lymphoma/Leukemia Molecular Profiling Project (LLMPP) and the Lunenburg Lymphoma Biomarker Consortium (LLBC). Finally, and key to clinical translation, are the collaborations with Canadian (CCTG) and US (ECOG, Alliance and SWOG) clinical trials groups.